Antimicrobial resistance tightens grip on Keralam, say latest report
The data for 2025 released by the Kerala Antimicrobial Resistance Surveillance Network show that State is now confronting AMR at several levels, from highly resistant pathogens in intensive care units to community-acquired bacteria such as Shigella, which is now resistant to common antibiotics. Drug-resistant bacteria seem to be the norm now, not the exception in Keralam’s hospitals
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
The Kerala Antimicrobial Resistance Surveillance Network (KARS-Net) released its antibiogram based on 2025 data, revealing a severe escalation in Antimicrobial Resistance (AMR) across the state. The report highlights that drug-resistant bacteria, including community-acquired strains, are now pervasive in both hospital and outpatient settings, indicating a critical public health challenge despite Kerala's advanced surveillance infrastructure.
UPSC Perspectives
Governance
The situation in Kerala underscores the complexities of health governance and the limitations of surveillance without behavioral change. While Kerala has successfully established a robust surveillance model through under the , this data collection has not translated into a reduction of AMR. This highlights a critical gap in stewardship—the coordinated interventions designed to improve and measure the appropriate use of antimicrobials. Effective governance requires not just monitoring, but strict regulation of antibiotic prescriptions, over-the-counter sales, and extensive public awareness campaigns regarding antibiotic literacy. The integration of state data into national systems like the and global systems like the by the is a positive step, but local enforcement remains the primary challenge.
Social
The emergence of AMR in community-acquired pathogens represents a severe threat to public health equity. The report notes high resistance in bacteria like Shigella and Salmonella, which are typically linked to unsafe food and water. When common infections become resistant to standard, affordable antibiotics (like ampicillin or ciprofloxacin), treatment requires more expensive, often more toxic, 'last-resort' drugs like carbapenems or colistin. This disproportionately impacts lower-income populations, turning manageable illnesses into severe health and financial crises. The shift of AMR from intensive care units to everyday, community settings means routine medical procedures and minor infections carry a significantly higher risk of morbidity and mortality.
Scientific
From a microbiological perspective, the data illustrates the alarming evolutionary adaptation of pathogens. The high rates of Extended-Spectrum Beta-Lactamases (ESBL) production in E. coli and Klebsiella (Gram-negative bacteria) indicate these organisms have developed enzymes that destroy common antibiotics. The growing resistance to carbapenems—often considered the 'last-resort' class of antibiotics—is particularly concerning. The report also highlights the difference between Gram-negative bacteria, which possess complex double-membrane structures and multiple resistance mechanisms, making them harder to treat, and Gram-positive bacteria like Methicillin-resistant Staphylococcus aureus (MRSA). The fact that colistin, a highly toxic older antibiotic reserved for the most intractable Gram-negative infections, is beginning to show emerging resistance (0.1%) signifies a perilous trajectory toward a 'post-antibiotic era' where common infections could once again become fatal.